Commercialization process of brain-machine interfaces accelerating, institutions closely monitoring concept stocks related to brain-machine interfaces.

Recently, China's brain-computer interface technology research has made new advances one after another. On May 13th, the Changchun Institute of Applied Chemistry of the Chinese Academy of Sciences announced that its research team has made new progress in the field of brain-computer interface technology for chronic pain treatment. On May 18th, China officially launched the first 128-channel fully implanted brain-computer interface system multi-center clinical trial. With policy support and technological breakthroughs, the commercialization process of brain-computer interfaces is accelerating. Data from the "China Brain-Computer Interface Commercialization Outlook Report" shows that since 2025, financing for brain-computer interface companies has entered an unprecedented active period, with the total financing amount in the first three months of 2026 already exceeding the full year of 2025. According to Securities Times Databao statistics, there are a total of 35 A-share stocks involved in the brain-computer interface industry chain, with a general retreat since May, with an average decline of 3.32%; 10 stocks have seen gains, with Darui Electronics, Guangpu Stock, and Hanwei Technology leading in cumulative gains, reaching 43.13%, 33.47%, and 18.7% respectively. Institutions are closely monitoring stocks related to brain-computer interfaces. Statistics show that 21 concept stocks related to brain-computer interfaces have received ratings from institutions, with Century Huatong, Kebomedical, iFlytek, Leap Medical, and Meihao Medical receiving ratings from 10 or more institutions.